Gowling WLG Advised Oxford BioTherapeutics On $1 Billion Partnership With Roche
Gowling WLG Advised Oxford BioTherapeutics On $1 Billion Partnership With Roche
Oxford BioTherapeutics and Roche will jointly endorse the selected targets before Roche takes over R&D and commercialisation of potential drugs based on antibodies directed against these targets.
Gowling WLG’s life sciences team has advised Oxford BioTherapeutics on a $1 billion agreement with Roche, a global leader in pharmaceuticals and diagnostics. The alliance will focus on multiple oncology targets or molecules in the human body that may be implicated in various cancers that will be identified by the OGAP-Verify discovery platform of Oxford BioTherapeutics. The platform aids selection of targets with qualities better suited for drug development. Oxford BioTherapeutics and Roche will jointly endorse the selected targets before Roche takes over R&D and commercialisation of potential drugs based on antibodies directed against these targets.
As per the agreement, Roche will provide Oxford BioTherapeutics with up to $36 million in upfront payments. Oxford BioTherapeutics also stands to receive payments above $1 billion along with royalties from potential sales. This is Roche’s third antibody-drug conjugate (ADC) pact of the year and highlights continued innovation and collaboration in the life sciences sector.
Of Counsel Dr Luke Kempton advised Oxford BioTherapeutics on this deal working with OBT General Counsel Patrick Duxbury.
Luke Kempton reportedly said: “We are proud to have supported Oxford BioTherapeutics in securing this significant partnership with Roche. This agreement not only highlights the strength of our client's innovative discovery platform but also sets the stage for groundbreaking advancements in oncology treatment."
Click to know more about Gowling WLG
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.
